A new daily weight loss pill can help patients with type 2 diabetes lose more weight and better control their blood sugar ...

Trial results published in the Lancet suggest the new appetite suppressing pill by pharmaceutical giant Eli Lilly worked best for patients with Type 2 diabetes, with two positive outcomes ...

Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes patients, giving a more ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

Comparing six diets, a new study found that the DASH diet in particular showed the strongest link to helping lower cognitive ...

Eli Lilly has spent months signaling it would challenge Novo Nordisk’s oral GLP-1 franchise. Now it has data to back that up.

Fish oil capsules sit on pharmacy shelves with quiet confidence. They promise heart strength, sharper thinking, and calmer ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be ...

LONDON, Feb 6 (Reuters) - Hims & Hers' (HIMS.N), opens new tab gambit to sell a $49 compounded version of Novo Nordisk's (NOVOb.CO), opens new tab Wegovy pill is rattling obesity shares, sparking ...